Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| UV1011CN | Other Identifier | Company Internal |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
It is a prospective, non-interventional, multi-center study. The primary objective of this study is to evaluate the image quality of Ultravist in patients requiring contrast-enhanced CT considering the routine use in patient population's, region's indication.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group 1 |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Iopromide (Ultravist, BAY86-4877) | Drug | CT enhancement for abdominal or pelvic scan. Generally doses of up to 1.5 g iodine per kg body weight are well tolerated |
|
| Measure | Description | Time Frame |
|---|---|---|
| Image quality evaluated by calculated CNR (Contrast to Noise Ratio) | 1 day |
| Measure | Description | Time Frame |
|---|---|---|
| Image quality evaluated by calculated SNR (Signal Noise Ratio) | 1 day | |
| Descriptive analysis of contrast medial injection protocol | 1 day | |
| Radiation dose (CTDIvol) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Patients undergoing contrast enhanced CT Imaging with Ultravist (iopromide) in abdomen and pelvis, including relevant vessels
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Bayer Study Director | Bayer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Many Locations | China |
Not provided
| ID | Term |
|---|---|
| C038192 | iopromide |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 1 day |